Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia:a population-based study in the Netherlands, 1989–2018
It is unclear how treatment advances impacted the population-level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first-line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands between 1989 and 2018 (N = 6232; median age, 70 years; 61% males) using data from the nationwide Netherlands Cancer Registry. Patients were grouped into three age groups (<65, 66–75 and >75 years) and four calendar periods. Overall, treatment with anti-neoplastic agents within 1 year post-diagnosi... Mehr ...
Verfasser: |
Amaador, Karima
Kersten, Marie José
Visser, Otto
Brink, Mirian
Posthuma, Eduardus F.M.
Minnema, Monique C.
Vos, Josephine M.I.
Dinmohamed, Avinash G. |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2022 |
Reihe/Periodikum: |
Amaador , K , Kersten , M J , Visser , O , Brink , M , Posthuma , E F M , Minnema , M C , Vos , J M I & Dinmohamed , A G 2022 , ' Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia : a population-based study in the Netherlands, 1989–2018 ' , British Journal of Haematology , vol. 196 , no. 3 , pp. 660-669 . https://doi.org/10.1111/bjh.17856 |
Schlagwörter: |
/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
/ SDG 3 - Good Health and Well-being |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-26841448 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://pure.eur.nl/en/publications/3792dfcc-9db9-4737-ad01-bbc407940b0a |